Journal of Genetic Counseling

, Volume 22, Issue 3, pp 291–295 | Cite as

Noninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis: the Position of the National Society of Genetic Counselors

  • Patricia L. Devers
  • Amy Cronister
  • Kelly E. OrmondEmail author
  • Flavia Facio
  • Campbell K. Brasington
  • Pamela Flodman
Professional Development Paper


The 1997 discovery of free fetal DNA in maternal plasma launched clinical researchers’ efforts to establish a reliable method for non-invasive prenatal testing for fetal genetic conditions. Various methods, including, but not limited to, massively parallel sequencing (MPS) and selective analysis of cell-free fetal DNA in maternal plasma, have recently been developed as highly sensitive and specific noninvasive screening tools for common fetal chromosome aneuploidies. Incorporating these new noninvasive technologies into clinical practice will impact the current prenatal screening paradigm for fetal aneuploidy, in which genetic counseling plays an integral role. The National Society of Genetic Counselors (NSGC) currently supports Noninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis (NIPT/NIPD) as an option for patients whose pregnancies are considered to be at an increased risk for certain chromosome abnormalities. NSGC urges that NIPT/NIPD only be offered in the context of informed consent, education, and counseling by a qualified provider, such as a certified genetic counselor. Patients whose NIPT/NIPD results are abnormal, or who have other factors suggestive of a chromosome abnormality, should receive genetic counseling and be given the option of standard confirmatory diagnostic testing.


Noninvasive prenatal diagnosis Aneuploidy screening Prenatal diagnosis Down syndrome Trisomy 13 Trisomy 18 Trisomy 21 Monosomy X Position Statement The National Society of Genetic Counselors Cellfree fetal DNA (cffDNA) 



We thank the NSGC Membership for the valuable insight and feedback they provided in the revision of this position statement. We also thank Molly Giammarco for her assistance to the taskforce. Finally, we would like to express our gratitude to Susan Hahn for her guidance and input throughout the process of creating this position statement.


  1. Ashoor, G., Syngelaki, A., Wang, E., Struble, C., Oliphant, A., Song, K., et al. (2012). Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method. Ultrasound in Obstetrics & Gynecology. doi: 10.1002/uog.12299 [Epub ahead of print].
  2. Benn, P., Borrell, A., Cuckle, H., Dugoff, L., Gross, S., Johnson, J. A., et al. (2012a). Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011. Prenatal Diagnosis, 32(1), 1–2. doi: 10.1002/pd.2919.Google Scholar
  3. Benn, P., Cuckle, H., & Pergament, E. (2012b). Non-invasive prenatal diagnosis for Down syndrome: the paradigm will shift, but slowly. Ultrasound in Obstetrics & Gynecology, 39(2), 127–130. doi: 10.1002/uog.11083.Google Scholar
  4. Bianchi, D. W., Platt, L. D., Goldberg, J. D., Abuhamad, A. Z., Sehnert, A. J., & Rava, R. P. (2012). Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing. Obstetrics and Gynecology, 119(5), 1–13.Google Scholar
  5. Chan, K., Yam, I., Leung, K. Y., Tang, M., Chan, T. K., & Chan, V. (2010). Detection of paternal alleles in maternal plasma for non-invasive prenatal diagnosis of beta-thalassemia: a feasibility study in southern Chinese. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 150(1), 28–33.PubMedGoogle Scholar
  6. Chiu, R. W., Chan, K. C., Gao, Y., Lau, V. Y., Zheng, W., Leung, T. Y., et al. (2008). Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 105(51), 20458–20463.PubMedGoogle Scholar
  7. Disability Rights Education and Defense Fund, Generations Ahead, National Women’s Health Network, Reproductive Health Technologies Project, and World Institute on Disability. (2008). The Prenatally and Postnatally Diagnosed Conditions Awareness Act. Retrieved from
  8. Fan, H. C., Blumenfeld, Y. J., Chitkara, U., Hudgins, L., & Quake, S. R. (2008). Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proceedings of the National Academy of Sciences of the United States of America, 105(42), 16266–16271.PubMedGoogle Scholar
  9. Lo, Y. M., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C. W., et al. (1997). Presence of fetal DNA in maternal plasma and serum. Lancet, 350(9076), 485–487.PubMedGoogle Scholar
  10. National Coalition for Health Professional Education in Genetics and National Society of Genetic Counselors. Non-Invasive Prenatal Testing (NIPT) Factsheet. Retrieved from
  11. Nicolaides, K. H., Syngelaki, A., Ashoor, G., Birdir, C., & Touzet, G. (2012). Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. American Journal of Obstetrics and Gynecology, 207, x.ex–x.ex.Google Scholar
  12. Norton, M. E., Brar, H., Weiss, J., Karimi, A., Laurent, L. C., Caughey, A. B., et al. (2012). Non-Invasive Chromosomal Evaluation (NICE) study: results of a multicenter, prospective, Cohort study for detection of fetal trisomy 21 and trisomy 18. American Journal of Obstetrics and Gynecology, 207(2), 137.e1–8. Epub 2012 Jun 1.Google Scholar
  13. NSGC (2010). NSGC Position Statement: Reproductive Freedom. Retrieved from
  14. Palomaki, G. E., Kloza, E. M., Lambert-Messerlian, G. M., Haddow, J. E., Neveux, L. M., Ehrich, M., et al. (2011). DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genetics in Medicine, 13(11), 913–920.PubMedGoogle Scholar
  15. Palomaki, G. E., Deciu, C., Kloza, E. M., Lambert-Messerlian, G. M., Haddow, J. E., Neveux, L. M., et al. (2012). DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genetics in Medicine, 14(3), 296–305. doi: 10.1038/gim.2011.73.PubMedGoogle Scholar
  16. Sparks, A. B., Struble, C. A., Wang, E. T., Song, K., & Oliphant, A. (2012). Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. American Journal of Obstetrics and Gynecology, 206(4), 319.e1–9. Epub 2012 Jan 26.Google Scholar

Copyright information

© National Society of Genetic Counselors, Inc. 2013

Authors and Affiliations

  • Patricia L. Devers
    • 1
    • 2
  • Amy Cronister
    • 3
  • Kelly E. Ormond
    • 4
    Email author
  • Flavia Facio
    • 5
  • Campbell K. Brasington
    • 6
  • Pamela Flodman
    • 7
  1. 1.University of North CarolinaChapel HillUSA
  2. 2.Verinata Health, IncSan CarlosUSA
  3. 3.Integrated GeneticsDushoreUSA
  4. 4.Department of Genetics and Stanford Center for Biomedical EthicsStanford UniversityStanfordUSA
  5. 5.BronxvilleUSA
  6. 6.Levine Children’s Hospital at Carolinas Medical CenterCharlotteUSA
  7. 7.Division of Genetics and Metabolism, Department of PediatricsUniversity of CaliforniaIrvineUSA

Personalised recommendations